Free Trial

Artelo Biosciences (ARTL) Competitors

Artelo Biosciences logo
$10.80 -0.24 (-2.13%)
Closing price 07/3/2025 03:49 PM Eastern
Extended Trading
$10.80 0.00 (0.00%)
As of 07/3/2025 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARTL vs. TXMD, NERV, EYEN, ALVR, ATHA, IBIO, EQ, CTXR, BGXX, and PHIO

Should you be buying Artelo Biosciences stock or one of its competitors? The main competitors of Artelo Biosciences include TherapeuticsMD (TXMD), Minerva Neurosciences (NERV), Eyenovia (EYEN), AlloVir (ALVR), Athira Pharma (ATHA), iBio (IBIO), Equillium (EQ), Citius Pharmaceuticals (CTXR), Bright Green (BGXX), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry.

Artelo Biosciences vs. Its Competitors

TherapeuticsMD (NASDAQ:TXMD) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

TherapeuticsMD has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.

Artelo Biosciences has a net margin of 0.00% compared to TherapeuticsMD's net margin of -114.07%. TherapeuticsMD's return on equity of -7.86% beat Artelo Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
TherapeuticsMD-114.07% -7.86% -5.46%
Artelo Biosciences N/A -226.99%-164.61%

In the previous week, Artelo Biosciences had 13 more articles in the media than TherapeuticsMD. MarketBeat recorded 13 mentions for Artelo Biosciences and 0 mentions for TherapeuticsMD. Artelo Biosciences' average media sentiment score of 0.24 beat TherapeuticsMD's score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
TherapeuticsMD Neutral
Artelo Biosciences Neutral

TherapeuticsMD has higher revenue and earnings than Artelo Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TherapeuticsMD$1.76M7.36-$2.18MN/AN/A
Artelo BiosciencesN/AN/A-$9.83M-$17.94-0.60

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 2.3% of TherapeuticsMD shares are owned by insiders. Comparatively, 0.8% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Artelo Biosciences has a consensus target price of $33.00, suggesting a potential upside of 205.70%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than TherapeuticsMD.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TherapeuticsMD
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Artelo Biosciences
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.20

Summary

Artelo Biosciences beats TherapeuticsMD on 8 of the 14 factors compared between the two stocks.

Get Artelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARTL vs. The Competition

MetricArtelo BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.50M$2.92B$5.56B$9.05B
Dividend YieldN/A2.44%5.24%3.99%
P/E Ratio-0.6021.5627.6520.23
Price / SalesN/A283.26419.56119.26
Price / CashN/A41.7026.2128.59
Price / Book2.037.538.035.65
Net Income-$9.83M-$55.14M$3.18B$249.15M
7 Day Performance56.22%4.61%2.93%3.28%
1 Month Performance60.64%0.90%1.72%3.95%
1 Year Performance34.77%5.40%34.39%20.98%

Artelo Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARTL
Artelo Biosciences
2.9672 of 5 stars
$10.80
-2.1%
$33.00
+205.7%
+35.3%$5.50MN/A-0.605
TXMD
TherapeuticsMD
N/A$1.11
+1.8%
N/A-25.8%$12.62M$1.76M0.00420Gap Up
NERV
Minerva Neurosciences
3.9632 of 5 stars
$1.77
flat
$5.00
+182.5%
-45.2%$12.38MN/A2.169News Coverage
Gap Down
EYEN
Eyenovia
2.6195 of 5 stars
$5.48
+30.2%
$2.00
-63.5%
-77.1%$12.14M$60K-0.0940Analyst Upgrade
High Trading Volume
ALVR
AlloVir
N/A$2.40
-6.6%
N/A-84.5%$12.10MN/A-0.12110Gap Up
High Trading Volume
ATHA
Athira Pharma
2.4815 of 5 stars
$0.30
-2.3%
$11.25
+3,700.7%
-87.0%$11.83MN/A-0.1440Gap Down
IBIO
iBio
2.095 of 5 stars
$0.71
-7.6%
$4.30
+503.6%
-61.1%$11.77M$375K0.00100High Trading Volume
EQ
Equillium
1.8 of 5 stars
$0.29
-11.3%
$3.00
+934.5%
-51.9%$11.68M$41.10M-0.7440Gap Up
CTXR
Citius Pharmaceuticals
2.4155 of 5 stars
$1.03
-4.6%
$54.50
+5,191.3%
-83.4%$11.48MN/A0.0020High Trading Volume
BGXX
Bright Green
N/AN/AN/AN/A$11.47MN/A-1.002Gap Down
PHIO
Phio Pharmaceuticals
2.1821 of 5 stars
$2.18
-4.0%
$14.00
+542.2%
-51.4%$10.87MN/A-0.2010

Related Companies and Tools


This page (NASDAQ:ARTL) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners